ClinicalTrials.gg
Active, not recruitingNCT06986811Updated Oct 20, 2026

CEB-01 in Pediatrics With Locally Resectable Abdominal Tumors

A Phase 2 interventional study of Standard surgery and CEB-01 in Locally Resectable Pediatrics Tumors, sponsored by CEBIOTEX. Active, not recruiting at 1 site in Spain. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by CEBIOTEX · Phase 2, Interventional, and Treatment

Updated Oct 20, 2026Now Active, not recruitingEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
Up to 18 Years
Sex
All
01

Study summary

The CEB-01 implant is a membrane containing SN-38, the active metabolite of irinotecan, an already authorized chemotherapeutic agent. After surgical removal of the abdominal cancer tumor, CEB-01 will be placed in the surgical bed for a local and sustained release of the chemotherapy. This is expected to delay or prevent local recurrence of abdominal tumors after surgery, while keeping a tolerable toxicity profile.

The study aims to assess the safety, tolerability, pharmacokinetics, and efficacy of CEB-01 in pediatric patients with locally resectable abdominal tumors including Soft Tissue Sarcoma (STS), high-risk Neuroblastoma (NB), Wilms tumor (WT), germ cell tumors (GCT), extracranial malignant rhabdoid tumor (eMRT), synovial sarcoma (SS), desmoplastic small round cell tumor (DSRCT) and fibrolamellar hepatocellular carcinoma (FL-HCC)

Read the detailed description

CEB-01-RLP01-CT trial is first-in-pediatrics, open label, exploratory, externally controlled clinical trial to evaluate safety, efficacy and pharmacokinetics of 7-ethyl-10-hydroxy-camptothecin (SN-38) formulated as a biocompatible polymeric nanofiber membrane (CEB-01) for treatment, in addition to standard of care, of pediatric patients from birth to less than 18 years of age with de novo or recurrent, locally resectable, abdominal tumors in comparison to standard of care.

The trial population will consist of 80 participants who fulfill all the inclusion and exclusion criteria, allocated in three cohorts:

Cohort 1: 20 participants with abdominal STS, open label treatment arm consisting of CEB-01 plus the standard of care (which may include surgery, with or without radiotherapy and/or chemotherapy). The outcomes will be compared to a well-matched population of about 10 participants from the same participating sites, including historical controls or contemporary controls.

Cohort 2: 20 participants with high-risk NB, open label treatment arm consisting of CEB-01 plus the standard of care (which may include surgery, with or without radiotherapy and/or chemotherapy). The outcomes will be compared to a well-matched population of about 10 participants from the same participating sites, including historical controls or contemporary controls.

Cohort 3: 20 participants with rare abdominal tumors including WT, GCT, eMRT, SS, DSRCT and FL-HCC, open label uncontrolled treatment arm to obtain additional safety and efficacy data.

For measurement of primary safety and efficacy endpoints, follow-up will consist of short-term evaluation at 365 ± 30 days and long-term evaluation at 1095 ± 30 days post-surgery as it is considered sufficient for the assessment of the therapeutic effect of CEB-01 regarding local recurrence.

For pharmacokinetic assessment, blood samples will be collected at baseline and at 9 different time points until 56 ± 4 days post-surgery.

For each participant the trial duration will be composed of a screening period for up to 28 days, one day for surgery and 1095 ± 30 days of follow-up.

A Data Safety Monitoring Board (DSMB) will review data in an unblinded fashion; details are given in the DSMB charter. The scheduled review will be performed by the DSMB once 10 treated participants have completed 6 months of follow-up. The DSMB can be convened at the request of the sponsor should safety signals be detected

02

Conditions studied

  • Locally Resectable Pediatrics Tumors

Keywords

  • CEB-01
  • SN-38
  • Locally resectable pediatrics tumors
03

In context

Lead sponsor

CEBIOTEX is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 20, 2026. See what changed

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible to participate in this trial, an individual must meet all the following criteria:

  1. ≤ 18 years.
  2. Participants must have a diagnosis of:

    1. De novo or recurrent abdominal soft-tissue sarcoma.
    2. De novo or recurrent high-risk neuroblastoma according to Children's Oncology Group (COG) risk classification, regardless of response to frontline therapy, diagnosed either by a former histologic verification of neuroblastoma and/or former demonstration of tumor cells in the bone marrow with increased urinary catecholamines at the time of study enrolment. Participants who were initially considered low or intermediate risk but were then reclassified as high risk are also eligible.
    3. Other tumors: recurrent Wilms tumor, de novo or recurrent Germ cell tumour, de novo or recurrent extracranial malignant rhabdoid tumor, de novo or recurrent synovial sarcoma, de novo or recurrent fibrolamellar hepatocellular carcinoma, and de novo or recurrent desmoplastic small round cell tumor.
  3. A histology assessment is required for enrolment of de novo cases, except for patients with high-risk neuroblastoma for which a radioiodine-labelled meta-iodobenzyl-guanidine (MIBG) test is positive and excess of production od catecholamines is confirmed. A new histology assessment is not required for enrolment of the recurrent cases, it will be obtained from the resected tumor to assess whether the histology is identical to the original tumor.
  4. Participants previously treated with irinotecan will be eligible if they have not had documented progressive disease during treatment.
  5. Participants might have more than one surgically removable lesion.
  6. Adequate liver, renal, hematological, and cardiac function as defined by biochemical and hematological parameters as follows: (Hb) >9.0 g/dL (with preoperative transfusion), >80.000/mm3 with intraoperative transfusion, ≥ 1.500/mm3 or below this threshold if there is clinical indication that the patient is on hematological recovery, albumin >3.0 g/dl, (ALT) and aspartate aminotransferase (AST) \<2.5 times the upper limit of normality [], \<2 times the ULN, creatinine \<1.0 mg/dl or > 60 ml/min.
  7. Participants must have fully recovered from the acute toxic effects (Grade 3 or above) of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this trial.
  8. Lansky or functional performance status score ≥ 50 at screening.
  9. Female participants of must have a negative urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at time of screening.
  10. Female and male participants of childbearing potential must be willing to use adequate throughout the study and for 6 months after surgery.
  11. greater than 6 months.
  12. The participant's legally authorized guardian must acknowledge in writing that consent to become a study subject has been obtained prior to any protocol screening procedures.

Exclusion criteria

Exclusion Criteria

An individual who meets any of the following criteria will be excluded from participation in this trial:

  1. lesions, that in the investigator's opinion will not jeopardize the assessment of efficacy and safety.
  2. Other within past 2 years except for in-situ cancers or basal/squamous cell skin cancer. Subjects with other malignancies are eligible if they are disease-free for at least 24 months or have a clinically stable concurrent malignancy not requiring tumor-directed treatment.
  3. Active bacterial, viral or fungal infection.
  4. Known history of active (HIV) infection, , or chronic liver disease. Testing is not required in the absence of clinical findings or suspicion.
  5. Impossibility of ensuring adequate follow-up.
  6. Participants who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
  7. to computed tomography (CT) scan.
  8. Major surgery within 14 days prior to the implant of study drug or still in recovery after experiencing surgical complications; neither tumor nor central line insertion are considered a major surgery.
  9. Other relevant concomitant illnesses.
  10. Participants´status post- stem cell transplant are not eligible.
  11. Participants with disease of any major organ system that would compromise their ability to withstand therapy.
  12. Patients with tumor size requiring CEB-01 implant that exceeds the maximum implantable surface area based on Body Surface Area (BSA) correction.
  13. Patients with known to SN-38 or any of the CEB-01 .
  14. Pregnancy or lactation. Pregnant women are excluded from this study; if the patient is a lactating mother, breastfeeding should be discontinued.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Standard surgery and CEB-01 implant after surgery

    Procedure/Surgery: Standard surgery The location and size of the tumor determine the type of surgery. Drug: CEB-01 It is novel formulation for local release of chemotherapy. It consists of a biocompatible and biodegradable nanofiber membrane made of poly(lactic-co-glycolic acid) (PLGA), which is loaded with the anti-tumor drug SN-38 and implanted in the surgical bed after tumor removal.

    Procedure: Standard surgery · Drug: CEB-01

  • Active comparator
    Active Comparator: Arm 2 standard surgery

    Procedure/Surgery: Standard surgery The location and size of the tumor determine the type of surgery.

    Procedure: Standard surgery

Interventions

  • ProcedureStandard surgery

    The location and size of the tumor determine the type of surgery.

  • DrugCEB-01

    It is novel formulation for local release of chemotherapy. It consists of a biocompatible and biodegradable nanofiber membrane made of poly(lactic-co-glycolic acid) (PLGA), which is loaded with the anti-tumor drug SN-38 and implanted in the surgical bed after tumor removal.

06

What researchers measure

Primary outcomes

  1. Frequency of Adverse Events (AEs) (Safety)

    Adverse Events (AE), serious and non-serious, with their frequency, severity, and relatedness to study drug and coded according to the most updated version of the Common Terminology Criteria for Adverse Events (CTCAE).

    Time frame: Through study completion, average 3 years

Secondary outcomes

  1. Progression-free survival (PFS)

    Defined as the time from surgery to objective tumor progression or death from any cause.

    Time frame: Through study completion, average 3 years

  2. Overall survival (OS).

    Defined as time from surgery to death from any cause.

    Time frame: Through study completion, average 3 years

  3. Local recurrence-free survival (LRFS)

    Defined as the time from surgery until the progression of the disease in the area of implanted CEB-01.

    Time frame: Through study completion, average 3 years

  4. New lesions either distant or metastatic by RECIST 1.1 (Response Evaluation Criteria in Solid Tumors, version 1.1)

    Number of new lesions either distant or metastatic by RECIST 1.1. (Response Evaluation Criteria in Solid Tumors, version 1.1)

    Time frame: Through study completion, average 3 years

  5. Area under the concentration-time curve (AUC0-inf) of SN-38 ( 7-ethyl-10-hydroxy Camptothecin)

    Represents the total SN-38 (f 7-ethyl-10-hydroxy Camptothecin) exposure in the peripheral blood across time

    Time frame: During 60 days

  6. Maximum concentration (Cmax) of SN-38.

    The highest concentration of SN-38 in the peripheral blood samples taken at sequential timepoints

    Time frame: During 60 days

  7. Time of maximum plasma concentration (Tmax) of SN38.

    Time from the surgery to the moment with the highest concentration of SN-38 in the peripheral blood samples taken at sequential timepoints

    Time frame: During 60 days

  8. Terminal half-life (t1/2) of SN-38

    The time required for the plasma concentration of SN-38 to fall by 50% from the Cmax

    Time frame: During 60 days

  9. Score of Quality of Life

    Quality of Life Questionnaire (QoL) using KIDSCREEN-27

    Time frame: Through study completion, average 3 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — No individual participant data (IPD) will be provided.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for May 2029, 48 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2025
First posted
May 23, 2025
StartActual
May 6, 2025
Primary completionEst.
May 2029
CompletionEst.
May 2029
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 20, 2026
Enrollment
60→80
Oct 20, 2026
Eligibility
7 inclusion criteria edited, 1 added, 1 removed; 5 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedDe novo or recurrent high-risk neuroblastoma according to Children's Oncology Group (COG) risk classification, regardless of response to frontline therapy, diagnosed either by a former histologic verification of neuroblastoma and/or former demonstration of tumourtumor cells in the bone marrow with increased urinary catecholamines at the time of study enrolment. Participants who were initially considered low or intermediate risk but were then reclassified as high risk are also eligible.
  • EditedOther tumourstumors: recurrent Wilms tumourtumor, de novo or recurrent Germ cell tumour, de novo or recurrent extracranial malignant rhabdoid tumourtumor, de novo or recurrent synovial sarcoma, de novo or recurrent fibrolamellar hepatocellular carcinoma, and de novo or recurrent desmoplastic small round cell tumourtumor.
  • EditedA histology assessment is required for enrolment of de novo cases, except for patients with high-risk neuroblastoma for which a radioiodine-labelled meta-iodobenzyl-guanidine (MIBG) test is positive and excess of production od catecholamines is confirmed. A new histology assessment is not required for enrolment of the recurrent cases, but it will be obtained from the resected tumourtumor to assess whether the histology is identical to the original tumourtumor.
  • RemovedAdequate liver, renal, haematological, and cardiac function.
  • AddedAdequate liver, renal, hematological, and cardiac function as defined by biochemical and hematological parameters as follows: hemoglobin (Hb) >9.0 g/dL (with preoperative transfusion), platelets >80.000/mm3 with intraoperative transfusion, absolute neutrophil count ≥ 1.500/mm3 or below this threshold if there is clinical indication that the patient is on hematological recovery, albumin >3.0 g/dl, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <2.5 times the upper limit of normality [ULN], bilirubin <2 times the ULN, creatinine <1.0 mg/dl or creatinine clearance > 60 ml/min.
  • EditedParticipants must have fully recovered from the acute toxic clinically relevant effects (Grade 3 or above) of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this trial.
  • EditedLandkyLansky or KarnosfskyKarnofsky functional performance status score ≥ 50 at screening.
  • EditedFemale participants of childbearing potential must have a negative urine betahumanbeta-human chorionic gonadotropin (beta-hCG) pregnancy test at time of screening.
  • EditedThe participant's legally authorized guardian must acknowledge in writing that consent to become a study subject has been obtained prior to any protocol screening procedures.
Exclusion criteria
  • ChangedBefore Metastatic lesions.Now Metastatic lesions, that in the investigator's opinion will not jeopardize the assessment of efficacy and safety.
  • EditedOther malignancies within past 2 years except for in-situ cancers or basal/squamous cell skin cancer. Subjects with other malignancies are eligible if they are disease-free for at least 24 months or have a clinically stable concurrent malignancy not requiring tumourtumor-directed treatment.
  • EditedMajor surgery within 14 days prior to the implant of study drug or still in recovery after experiencing surgical complications; neither tumourtumor biopsy nor central line insertion are considered a major surgery.
  • EditedParticipant' Participants´status post-allogeneic stem cell transplant are not eligible.
  • EditedPatients with tumourtumor size requiring CEB-01 implant that exceeds the maximum implantable surface area based on Body Surface Area (BSA) correction.
Oct 20, 2026
Secondary outcomes
1 added, 2 description edited
What changed in the outcomes
  • AddedScore of Quality of LifeTime frame: Through study completion, average 3 years
  • DescriptionProgression-free survival (PFS): how it is measured was reworded
  • DescriptionTerminal half-life (t1/2) of SN-38: how it is measured was reworded
Oct 20, 2026
Title
CEB-01 in PaediatricsPediatrics With Locally Resectable Abdominal TumoursTumors
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Recruiting→Active, not recruiting
    Enrollment 60→80
    Eligibility 7 inclusion criteria edited, 1 added, 1 removed; 5 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedDe novo or recurrent high-risk neuroblastoma according to Children's Oncology Group (COG) risk classification, regardless of response to frontline therapy, diagnosed either by a former histologic verification of neuroblastoma and/or former demonstration of tumourtumor cells in the bone marrow with increased urinary catecholamines at the time of study enrolment. Participants who were initially considered low or intermediate risk but were then reclassified as high risk are also eligible.
    • EditedOther tumourstumors: recurrent Wilms tumourtumor, de novo or recurrent Germ cell tumour, de novo or recurrent extracranial malignant rhabdoid tumourtumor, de novo or recurrent synovial sarcoma, de novo or recurrent fibrolamellar hepatocellular carcinoma, and de novo or recurrent desmoplastic small round cell tumourtumor.
    • EditedA histology assessment is required for enrolment of de novo cases, except for patients with high-risk neuroblastoma for which a radioiodine-labelled meta-iodobenzyl-guanidine (MIBG) test is positive and excess of production od catecholamines is confirmed. A new histology assessment is not required for enrolment of the recurrent cases, but it will be obtained from the resected tumourtumor to assess whether the histology is identical to the original tumourtumor.
    • RemovedAdequate liver, renal, haematological, and cardiac function.
    • AddedAdequate liver, renal, hematological, and cardiac function as defined by biochemical and hematological parameters as follows: hemoglobin (Hb) >9.0 g/dL (with preoperative transfusion), platelets >80.000/mm3 with intraoperative transfusion, absolute neutrophil count ≥ 1.500/mm3 or below this threshold if there is clinical indication that the patient is on hematological recovery, albumin >3.0 g/dl, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <2.5 times the upper limit of normality [ULN], bilirubin <2 times the ULN, creatinine <1.0 mg/dl or creatinine clearance > 60 ml/min.
    • EditedParticipants must have fully recovered from the acute toxic clinically relevant effects (Grade 3 or above) of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this trial.
    • EditedLandkyLansky or KarnosfskyKarnofsky functional performance status score ≥ 50 at screening.
    • EditedFemale participants of childbearing potential must have a negative urine betahumanbeta-human chorionic gonadotropin (beta-hCG) pregnancy test at time of screening.
    • EditedThe participant's legally authorized guardian must acknowledge in writing that consent to become a study subject has been obtained prior to any protocol screening procedures.
    Exclusion criteria
    • ChangedBefore Metastatic lesions.Now Metastatic lesions, that in the investigator's opinion will not jeopardize the assessment of efficacy and safety.
    • EditedOther malignancies within past 2 years except for in-situ cancers or basal/squamous cell skin cancer. Subjects with other malignancies are eligible if they are disease-free for at least 24 months or have a clinically stable concurrent malignancy not requiring tumourtumor-directed treatment.
    • EditedMajor surgery within 14 days prior to the implant of study drug or still in recovery after experiencing surgical complications; neither tumourtumor biopsy nor central line insertion are considered a major surgery.
    • EditedParticipant' Participants´status post-allogeneic stem cell transplant are not eligible.
    • EditedPatients with tumourtumor size requiring CEB-01 implant that exceeds the maximum implantable surface area based on Body Surface Area (BSA) correction.
    Secondary outcomes 1 added, 2 description edited
    What changed in the outcomes
    • AddedScore of Quality of LifeTime frame: Through study completion, average 3 years
    • DescriptionProgression-free survival (PFS): how it is measured was reworded
    • DescriptionTerminal half-life (t1/2) of SN-38: how it is measured was reworded
    Title CEB-01 in PaediatricsPediatrics With Locally Resectable Abdominal TumoursTumors
    + 8 other changes: index terms, verification date, responsible party, description, conditions, design details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06986811
Lead sponsor
CEBIOTEX
Collaborators
CEBIOTEX S.L.
Responsible party
Sponsor
First posted
May 23, 2025
Start date
May 6, 2025
Primary completion
May 2029 (estimated)
Completion
May 2029 (estimated)
Last update
Oct 20, 2026

Study contacts

Marta Pilar Martin Gimenez, M.D.; Ph.D.
principal investigator · Hospital Sant Joan de Deu

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CEB-01

Start the discussion